Kymera Therapeutics (KYMR) Q3 2026 earnings review
Kymera's new autoimmune pill passes human tests, while trial costs rise
Kymera Therapeutics, a biotech developing daily pills that destroy disease-causing proteins, cleared a key human test while its trial costs climbed. Chief executive Nello Mainolfi reported that its second pill, KT-579, cut its target protein by at least 90% in healthy volunteers with side effects matching placebo. Meanwhile, research spending rose 73% from a year ago to $129 million as partner revenue dropped to zero.
| KT-579 Phase 1 IRF5 protein reduction | >=90% target: >90% reduction |
|---|---|
| Research and development spending | $128.5M +73% from a year ago |
| Cash and marketable securities | $1.65B $1.50B last quarter |
| Full-year collaboration revenue outlook | Unchanged zero revenue planned for Q4 |
⚖️ Verdict: 🟢 Bullish
The story got better because the company proved its second autoimmune pill works in humans ahead of schedule and finished patient visits in its main eczema trial. That removes the early human translation doubt on KT-579 before the year-end readout for its lead drug, KT-621. One caution: the quarterly loss reached $132 million as late-stage trial prep ramped up.
The question now is whether KT-621 can match the skin clearance of injectable drugs in its year-end eczema readout without a high placebo response blurring the result. Either the pill delivers clear shot-like relief that justifies a large Phase 3 program, or a modest gap over placebo leaves it vulnerable to rival pills. Top-line data from the BROADEN2 eczema trial by the end of 2026 will decide it.
🐂 Bull Case
KT-579 Clears Its First Human Test Early
KT-579 is Kymera's daily pill designed to destroy IRF5, a protein that drives autoimmune diseases such as lupus. Chief executive Nello Mainolfi had promised initial healthy-volunteer results in the fourth quarter, and the key question was whether animal results would hold up in people. "These findings exceed our expectations in terms of depth of degradation, safety and pathway suppression measured by downstream cytokines and gene transcripts," Mainolfi said.
- IRF5 protein reduction in blood: 90% or more across multiple doses, reaching maximum effect by the third dose level
- Inflammatory marker reductions at Day 14: 88% for TNF-alpha, 87% for IL-12/23p40, 94% for IL-1-beta, and 98% for IFN-beta
- Safety: "The safety profile of KT-579 was comparable to placebo", with no serious side effects or dropouts
These results beat the 50% to 80% marker reduction target that management set last quarter, and the drug lowered IRF5 in skin as well as blood. Because healthy volunteers do not have active autoimmune disease, this trial softens the translation risk rather than settling it. The biotech company now plans to test KT-579 in about 30 lupus patients over 16 weeks in the LUMORA trial, starting by early 2027.
What to watch: the start of the LUMORA Phase 1b lupus study by early 2027 and its first patient data later on. Strong marker and symptom improvements in lupus patients would prove the pill works in sick people, not just stimulated blood samples.
Eczema Trial Finishes Dosing for Year-End Readout
KT-621 is Kymera's lead daily pill, built to clear STAT6, the protein behind allergic inflammation in eczema and asthma. The drug maker wants KT-621 to offer shot-like relief in a pill for over 140 million patients with Type 2 inflammatory diseases. In October, the last patient finished the 16-week visit in the BROADEN2 Phase 2b eczema trial, after the company hired chief medical officer Terence Rooney and program leader Elizabeth Laws in July.
Finishing all patient visits locks in the timeline for the company's biggest catalyst, which management already pulled forward by about six months earlier this year. The Massachusetts group remains on track to report top-line eczema results by the end of 2026 and start Phase 3 testing by mid-2027, while its BREADTH Phase 2b asthma trial continues enrolling for a late-2027 readout.
What to watch: top-line week-16 skin clearance and safety results from the BROADEN2 eczema trial by the end of 2026. Clear skin improvement over placebo without new side effects would support starting Phase 3 trials in mid-2027.
🐻 Bear Case
Research Spending Jumps 73% as Partner Revenue Stops
Kymera has no commercial drugs on the market, so it funds its trials with cash on hand and occasional milestone payments from partners Sanofi and Gilead Sciences. After collecting $99.4 million of partner revenue in the first half of 2026, the company booked zero revenue in the third quarter and confirmed that "The Company does not expect to recognize additional collaboration revenue in 2026".
- Research and development (R&D) spending: $128.5 million, up 73.4% from a year ago and up 7.6% from last quarter
- Cash R&D spending, excluding stock pay: $117.6 million by our math, up 79.0% from a year ago
- Net loss: $132.0 million, or $1.32 per share, compared with $82.2 million a year ago
The company said R&D rose because it spent more on the STAT6 clinical trials, early discovery work, and hiring across the research team. Because partner revenue dropped to zero while trial costs climbed, the quarterly net loss widened by 60.6% from a year ago. By our math, total cash operating expenses excluding stock pay reached $128.4 million this quarter, and Phase 3 trials have not even started yet.
What to watch: fourth-quarter R&D spending and the first-half 2027 budget when Phase 3 eczema preparations begin. Another large step-up in quarterly spending would eat into the cash buffer faster than the current 2029 outlook assumes.
Kymera Quietly Dropped Its Ten-Drug Goal
At the end of 2024, Kymera told investors it was on a path to put a total of 10 experimental degrader drugs into human trials by the end of 2026. In this quarter's release, Mainolfi called KT-579 "our 7 th degrader to enter the clinic", and the company now states "a goal to deliver at least one new development candidate per year".
With two months left in 2026 and no other drug ready to start human dosing this year, the biotech firm will finish 2026 at seven clinical programs rather than 10. Management never announced that it was dropping the 10-drug target after shelving earlier cancer and immune programs. Shifting the goal to one preclinical candidate a year lowers the pace of new shots on goal from its research engine.
What to watch: whether Kymera names a new development candidate for human testing by the end of 2026. Missing the one-candidate-per-year goal would show that the early research pipeline is slowing while money shifts to late-stage trials.
Risks this quarter didn't answer
Several standing risks around the year-end eczema readout, rival drugs, and the balance sheet could not be tested from the third-quarter press release alone.
- BROADEN2 trial bar and placebo rate: management has not shared the statistical powering or baseline patient severity, which the year-end 2026 readout will test.
- Safety in 16-week eczema dosing: whether KT-621 causes eye inflammation or other side effects in patients remains open until the year-end 2026 data release.
- STAT6 competition: how Kymera positions KT-621 against Pfizer's Phase 2 inhibitor and the Nurix and Sanofi degrader requires the conference call Q&A.
- Source of the third-quarter cash increase: cash rose by $141 million despite a $132 million net loss, and the quarterly filing's cash flow statement will show how much came from share sales.
💲 Other KPIs
Cash, cash equivalents and marketable securities rose by $141.0 million from last quarter and grew 68.2% from a year ago. Even with $128.4 million in cash operating costs by our math and a $20 million Sanofi milestone collection, the balance climbed, pointing to financing inflows not detailed in the release.
The average share count rose 14.7% from a year ago and 2.0% from last quarter, adding about 1.9 million shares sequentially. That 2.0% sequential increase helps explain why cash on the balance sheet rose during a quarter with no revenue, though the exact proceeds await the quarterly filing.
Overhead costs — spending on legal fees, executives, and office space — rose 8.0% from a year ago but fell 11.4% from $21.1 million last quarter. Stock-based pay made up $7.9 million of the total, leaving cash overhead at $10.8 million by our math.
Accrued expenses — bills for clinical trials and services that Kymera has recorded as costs but not yet paid in cash — jumped 49.8% from $42.3 million at the end of 2025. Delaying cash payments on those rising trial bills kept more cash on the balance sheet at quarter-end.
🔮 Guidance
Unchanged. The biotech group reiterated that it does not expect to book any more partner revenue in 2026 after recording $99.4 million in the first half. By our math, that leaves fourth-quarter collaboration revenue at zero, compared with $2.9 million in the fourth quarter of last year, until a partner hits a new clinical milestone in 2027 or later.
Unchanged. Management still expects its $1.65 billion cash pile to fund operations into 2029, past the upcoming eczema, asthma, and lupus readouts. By our math, funding the next 10 quarters into early 2029 allows an average net cash draw of about $165 million per quarter, well above this quarter's $128.4 million in cash operating expenses.
❓ Key Questions
Why did cash rise by $141 million this quarter?
Cash and investments climbed from $1.50 billion to $1.65 billion even though Kymera posted a $132 million net loss and zero revenue. The release omits a cash flow statement, leaving unclear how much came from ATM share sales versus working capital.
What efficacy gap over placebo must KT-621 hit?
With the BROADEN2 eczema trial now finished dosing and top-line data due by year-end, management still has not shared the trial's statistical powering or the placebo-adjusted skin clearance score it views as a commercial win.
How much will the KT-621 Phase 3 program cost?
R&D spending already hit $128.5 million this quarter before any Phase 3 study has begun. Investors need to know how many Phase 3 studies are included inside the 2029 cash runway and when a partner or new financing would be needed.
Will KT-579 enter inflammatory bowel disease trials next?
Following strong Phase 1 healthy-volunteer data, Kymera outlined a 30-patient lupus trial starting by early 2027. Management also listed rheumatoid arthritis and inflammatory bowel disease as targets, but gave no timeline for testing outside lupus.